

Cancer Cachexia: Drug Development Pipeline Study, H1 2018

<https://marketpublishers.com/r/C45AAF0AF7CEN.html>

Date: March 2018

Pages: 47

Price: US\$ 895.00 (Single User License)

ID: C45AAF0AF7CEN

Abstracts

Cancer Cachexia pipeline comprises of 17 drugs under development as of March 2018. Of these, 1 drug is in Phase 1 and 4 drugs in phase 2 with 1 drug in Phase 3. Further, 10 drugs are in Pre-clinical stage and 1 drug is in research phase.

26 companies are developing the pipeline for Cancer Cachexia. Of this, Helsinn Healthcare, S.A has the most advanced stage drug in pipeline. Ghrelin receptor is the most targeted area for most compounds.

No compounds have been awarded orphan drug status for PAH.

Anorexia/Cachexia Syndrome is a serious complication in patients with advanced cancer where the patients witness a wasting syndrome caused by Anorexia and loss of weight. The market is estimated to be around \$2 billion. While Anorexia refers to loss of appetite, the term Cachexia corresponds to weight loss including lean body mass and fat.

Around 5 million people are estimated to be affected by Anorexia/Cachexia and most of the patients have a short survival time. Further, these patients react poorly against chemotherapy treatments. Body composition changes are also observed in the patients including muscle wasting and lean tissue decrease.

The most comprehensive pipeline review “Cancer Cachexia- Drug Development Pipeline Study” provides in-depth analysis and update information on Cancer Cachexia pipeline drugs. Current status of all the drugs in the Cancer Cachexia pipeline is provided in the research work.

The report provides detailed analysis of Cancer Cachexia pipeline including companies involved, drugs in different stages of development, drug development details across regions (Region (North America, Europe, Asia Pacific and Rest of the World). Further, the Cancer Cachexia report identifies aspects important in modifying industry market scenarios, increasing opportunities and list of potential companies that impact the Cancer Cachexia industry.

Scope:

- All latest industry developments and their impact on projects and companies
- Complete overview of global Cancer Cachexia therapy options and treatments
- The pipeline study reviews drug details for Cancer Cachexia by developing companies, institutions, mechanism of action, Target, Route, Phase (pre-clinical/ Discovery, Phase 1, Phase 2, Phase 3, Pre-Registration, IND/ NDA), molecule
- Mergers, Acquisitions, licensing, co-development and project acquisition news for Cancer Cachexia market
- Cancer Cachexia drugs being developed in combination with other drugs are also detailed
- Company wise drugs listed with their current status, partners and news updates

Contents

1 TABLE OF CONTENTS

1.1 LIST OF FIGURES

1.2 LIST OF TABLES

2 EXECUTIVE SUMMARY

2.1 DISEASE OVERVIEW

2.2 PIPELINE SNAPSHOT

2.3 PIPELINE DRUGS BY PHASE

2.4 PIPELINE DRUGS BY COMPANY

2.5 PIPELINE DRUGS BY MECHANISM OF ACTION

3 CANCER CACHEXIA- COMPANY WISE PIPELINE ANALYSIS

3.1 ABREOS BIOSCIENCES, INC. PIPELINE, H1 2018

3.2 AAVOGEN PIPELINE, H1 2018

3.3 ACACIA PHARMA PIPELINE, H1 2018

3.4 AETERNA ZENTARIS INC. PIPELINE, H1 2018

3.5 AVEO ONCOLOGY PIPELINE, H1 2018

3.6 ENERGENESIS BIOMEDICAL CO., LTD PIPELINE, H1 2018

3.7 EXTEND BIOSCIENCES PIPELINE, H1 2018

3.8 HELSINN HEALTHCARE, S.A PIPELINE, H1 2018

3.9 INCYTE CORPORATION PIPELINE, H1 2018

3.10 NEOMED PIPELINE, H1 2018

3.11 NGM BIOPHARMACEUTICALS PIPELINE, H1 2018

3.12 PARADIGM BIOPHARMA PIPELINE, H1 2018

3.13 RAQUALIA PHARMA PIPELINE, H1 2018

3.14 STEMMED LTD PIPELINE, H1 2018

3.15 TCI PEPTIDE THERAPEUTICS PIPELINE, H1 2018

3.16 VIKING THERAPEUTICS PIPELINE, H1 2018

4 CANCER CACHEXIA DRUG SNAPSHOTS

4.1 CRYPTIC-FC DRUG DETAILS

4.1.1 Snapshot

4.1.2 Overview

- 4.1.3 Mechanism of Action
- 4.1.4 Current Status
- 4.1.5 Trial Details
- 4.2 APD209DRUG DETAILS
 - 4.2.1 Snapshot
 - 4.2.2 Overview
 - 4.2.3 Mechanism of Action
 - 4.2.4 Current Status
 - 4.2.5 Trial Details
- 4.3 MACIMORELIN DRUG DETAILS
 - 4.3.1 Snapshot
 - 4.3.2 Overview
 - 4.3.3 Mechanism of Action
 - 4.3.4 Current Status
 - 4.3.5 Trial Details
- 4.4 RUXOLITINIB PHOSPHATE DRUG DETAILS
 - 4.4.1 Snapshot
 - 4.4.2 Overview
 - 4.4.3 Mechanism of Action
 - 4.4.4 Current Status
 - 4.4.5 Trial Details
- 4.5 AV-380 DRUG DETAILS
 - 4.5.1 Snapshot
 - 4.5.2 Overview
 - 4.5.3 Mechanism of Action
 - 4.5.4 Current Status
 - 4.5.5 Trial Details
- 4.6 IP1510 DRUG DETAILS
 - 4.6.1 Snapshot
 - 4.6.2 Overview
 - 4.6.3 Mechanism of Action
 - 4.6.4 Current Status
 - 4.6.5 Trial Details
- 4.7 RQ-00433412 DRUG DETAILS
 - 4.7.1 Snapshot
 - 4.7.2 Overview
 - 4.7.3 Mechanism of Action
 - 4.7.4 Current Status
- 4.8 VK 5211 DRUG DETAILS

- 4.8.1 Snapshot
- 4.8.2 Overview
- 4.8.3 Mechanism of Action
- 4.8.4 Current Status
- 4.8.5 Trial Details
- 4.9 ANAMORELIN DRUG DETAILS
 - 4.9.1 Snapshot
 - 4.9.2 Overview
 - 4.9.3 Mechanism of Action
 - 4.9.4 Current Status
 - 4.9.5 Trial Details
- 4.10 HM03 DRUG DETAILS
 - 4.10.1 Snapshot
 - 4.10.2 Overview
 - 4.10.3 Mechanism of Action
 - 4.10.4 Current Status
- 4.11 AVGN7 DRUG DETAILS
 - 4.11.1 Snapshot
 - 4.11.2 Overview
 - 4.11.3 Mechanism of Action
 - 4.11.4 Current Status
 - 4.11.5 Trial Details
- 4.12 C188-9 DRUG DETAILS
 - 4.12.1 Snapshot
 - 4.12.2 Overview
 - 4.12.3 Mechanism of Action
 - 4.12.4 Current Status
- 4.13 ENERGI-F706 DRUG DETAILS
 - 4.13.1 Snapshot
 - 4.13.2 Overview
 - 4.13.3 Mechanism of Action
 - 4.13.4 Current Status
 - 4.13.5 Trial Details
- 4.14 EXT 400-GHRELIN DRUG DETAILS
 - 4.14.1 Snapshot
 - 4.14.2 Overview
 - 4.14.3 Mechanism of Action
 - 4.14.4 Current Status
- 4.15 NEO1940 DRUG DETAILS

- 4.15.1 Snapshot
- 4.15.2 Overview
- 4.15.3 Mechanism of Action
- 4.15.4 Current Status
- 4.16 CANCER CACHEXIA THERAPEUTIC DRUG DETAILS
 - 4.16.1 Snapshot
 - 4.16.2 Overview
 - 4.16.3 Mechanism of Action
 - 4.16.4 Current Status
- 4.17 NGM120 DRUG DETAILS
 - 4.17.1 Snapshot
 - 4.17.2 Overview
 - 4.17.3 Mechanism of Action
 - 4.17.4 Current Status
 - 4.17.5 Trial Details

5 RECENT DEVELOPMENTS IN CANCER CACHEXIA PIPELINE

- 5.1 PROMISING NEW DRUG DEVELOPMENT COULD HELP TREAT CACHEXIA - APRIL 2017
- 5.2 POTENTIAL TARGET FOR TREATING CANCER CACHEXIA - OCTOBER 2017
- 5.3 SCIENTISTS BLOCK CANCER-INDUCED CACHEXIA IN PRECLINICAL TRIALS - OCTOBER 2017

6 APPENDIX

- 6.1 ABOUT VPA RESEARCH
- 6.2 SOURCES AND RESEARCH METHODOLOGY

List Of Figures

LIST OF FIGURES

Figure 1: Cancer Cachexia Pipeline by Phase, H1- 2018

Figure 2: Cancer Cachexia Pipeline by Companies, H1- 2018

Figure 3: Company wise Pipeline Drug Phases, H1- 2018

Figure 4: Cancer Cachexia Pipeline by Mechanism of Action, H1- 2018

Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018

List Of Tables

LIST OF TABLES

- Table 1: Cancer Cachexia Pipeline by Phase, H1- 2018
- Table 2: Cancer Cachexia Pipeline by Companies, H1- 2018 (1)
- Table 3: Cancer Cachexia Pipeline by Mechanism of Action, H1- 2018
- Table 4: ABREOS BIOSCIENCES, INC. - Cancer Cachexia Pipeline, H1- 2018
- Table 5: AAVogen Cancer Cachexia Pipeline, H1- 2018
- Table 6: Acacia Pharma Cancer Cachexia Pipeline, H1- 2018
- Table 7: Aeterna Zentaris Inc. - Cancer Cachexia Pipeline, H1- 2018
- Table 8: AVEO Oncology- Cancer Cachexia Pipeline, H1- 2018
- Table 9: Energenesis Biomedical Co., Ltd - Cancer Cachexia Pipeline, H1- 2018
- Table 10: Extend Biosciences - Cancer Cachexia Pipeline, H1- 2018
- Table 11: Helsinn Healthcare, S.A - Cancer Cachexia Pipeline, H1- 2018
- Table 12: Incyte Corporation - Cancer Cachexia Pipeline, H1- 2018
- Table 13: Neomed - Cancer Cachexia Pipeline, H1- 2018
- Table 14: NGM Biopharmaceuticals - Cancer Cachexia Pipeline, H1- 2018
- Table 15: Paradigm Biopharma - Cancer Cachexia Pipeline, H1- 2018
- Table 16: RaQualia Pharma - Cancer Cachexia Pipeline, H1- 2018
- Table 17: StemMed Ltd - Cancer Cachexia Pipeline, H1- 2018
- Table 18: TCI Peptide Therapeutics - Cancer Cachexia Pipeline, H1- 2018
- Table 19: Viking Therapeutics - Cancer Cachexia Pipeline, H1- 2018

I would like to order

Product name: Cancer Cachexia: Drug Development Pipeline Study, H1 2018

Product link: <https://marketpublishers.com/r/C45AAF0AF7CEN.html>

Price: US\$ 895.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C45AAF0AF7CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970